In the Increlex (native mecasermin) FDA-approved program, hypoglycemia was reported in 42% of subjects, with five subjects experiencing severe episodes requiring assistance and four experiencing seizures or loss of consciousness
Biochemical characterization of Drosophila glutathione S-transferases D1 and D21 [PMID: 7961718] Laboratory literature summary: Biochemical characterization of Drosophila glutathione S-transferases D1 and D21
Studies show the peptide counteracts both arterial and venous thrombosis
Mast cell activation syndrome, or MCAS, is an immunological condition where the mast cells in the body release excessive amounts of chemical mediators such as histamine, leading to symptoms such as hives, flushing, rashes, swelling, low blood pressure, dizziness, brain fog, breathing difficulties, and even anaphylaxis
As an investigational peptide with extensive clinical trial data, it offers researchers a well-characterized tool for studying amylin receptor biology [18]
This comparison breaks down what each does, how they differ, and why their combination (CagriSema) may represent the next leap in obesity pharmacotherapy